

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Molteni *et al.*

Application No.: 10/589,087

Filing Date: 10/08/2008

For: COMPOUNDS AND
COMPOSITIONS AS LXR
MODULATORS

Confirmation No.: 5455

Art Unit: 1625

Atty. Docket No. PAT034395-US-PCT

Examiner: MORRIS, Patricia L

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The reference cited in the attached forms PTO/SB/08A and PTO/SB08B is being called to the attention of the Examiner, specifically compound 139 on page 39 of the cited reference. Only copies of foreign and non-patent references are enclosed. It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom. As provided by 37 C.F.R. §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Although it is believed that no fees are due with submission of this filing, should there be any fees due in connection with this filing, the Commissioner is authorized to deduct such fees, or credit any overpayment, to Deposit Account **No. 50-1885** referencing docket PAT034395-US-PCT.

Respectfully submitted,

Date: May 12, 2011

/Daniel E. Raymond, Reg. # 53,504/

Daniel E. Raymond

Daniel E. Raymond, Ph.D., Reg. No. 53,504
The Genomics Institute of the Novartis Research Foundation
10675 John Jay Hopkins Drive, San Diego, CA 92121

Customer No.: 29490

Phone: (858) 812 1617; Fax: (858) 812 1909